Please login to the form below

Not currently logged in
Email:
Password:

BMS’ Dr Mike Burgees joins Turnstone Biologics

He joins the immuno-oncology group as its president of R&D

Turnstone Biologics, a North American clinical-stage immuno-oncology company, has appointed Dr Mike Burgees as its president of research and development, a role that will see him lead all functions in the R&D organisation, including preclinical and clinical development.

Dr Burgees has over 20 years’ experience in drug development, most recently as senior vice president, cardiovascular, fibrosis and immunoscience at Bristol-Myers Squibb (BMS).

He said: “Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer.

“I look forward to working closely with Turnstone’s experienced team and founders, who are driven by science and innovation, to bring these breakthrough medicines to patients.”

Prior to his time at BMS, Dr Burgees held several senior leadership positions at Roche, including acting global head of Roche Pharma Research and Early Development (pRED) and senior vice president and global head of oncology research and early development.

Sammy Farah, president and chief executive officer, Turnstone Biologics, said: “Mike is one of the most respected research and development leaders in the pharmaceutical industry, and has successfully led the global development and registration of several anti-cancer medicines.

“Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful immuno-oncology R&D capabilities.”

6th December 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics